Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Globalization of Traditional Chinese Medicine: what are the issues for ensuring evidence-based diagnosis and therapy?

Fears R, Griffin GE, Larhammar D, Ter Meulen V, van der Meer JWM.

J Intern Med. 2019 Nov 7. doi: 10.1111/joim.12989. [Epub ahead of print] No abstract available.

PMID:
31697414
2.

Urgent action is needed to protect human health from the increasing effects of climate change.

Hobbhahn N, Fears R, Haines A, Ter Meulen V.

Lancet Planet Health. 2019 Aug;3(8):e333-e335. doi: 10.1016/S2542-5196(19)30114-7. No abstract available.

3.

Win-wins for health and climate - new report.

Fears R, Hobbhahn N, Ter Meulen V, Haines A.

Nature. 2019 Jul;571(7763):36. doi: 10.1038/d41586-019-02030-8. No abstract available.

PMID:
31267057
4.

Scientific opportunities for nutrition security.

Fears R, Ter Meulen V.

Lancet. 2019 Jun 1;393(10187):2200. doi: 10.1016/S0140-6736(19)30223-5. No abstract available.

PMID:
31162081
5.

Transforming food systems to deliver healthy, sustainable diets-the view from the world's science academies.

Fears R, Canales C, Ter Meulen V, von Braun J.

Lancet Planet Health. 2019 Apr;3(4):e163-e165. doi: 10.1016/S2542-5196(19)30038-5. Epub 2019 Feb 26. No abstract available.

6.

Assessing Security Implications of Genome Editing: Emerging Points From an International Workshop.

Fears R, Ter Meulen V.

Front Bioeng Biotechnol. 2018 Mar 28;6:34. doi: 10.3389/fbioe.2018.00034. eCollection 2018. No abstract available.

7.

Scientific opportunities for food and nutrition security.

Fears R, Ter Meulen V, von Braun J.

Lancet Planet Health. 2018 Jan;2(1):e2-e3. doi: 10.1016/S2542-5196(17)30175-4. Epub 2018 Jan 9. No abstract available.

8.

Assessing and regulating homeopathic products.

Fears R, Griffin G, Larhammar D, Ter Meulen V, van der Meer JWM.

J Intern Med. 2017 Dec;282(6):563-565. doi: 10.1111/joim.12676. Epub 2017 Sep 25. No abstract available.

PMID:
28944510
9.

How should the applications of genome editing be assessed and regulated?

Fears R, Ter Meulen V.

Elife. 2017 Apr 4;6. pii: e26295. doi: 10.7554/eLife.26295.

10.

What next for gain-of-function research in Europe?

Fears R, ter Meulen V.

Elife. 2015 Dec 30;4. pii: e13035. doi: 10.7554/eLife.13035.

11.

European Academies Advise on Gain-of-Function Studies in Influenza Virus Research.

Fears R, ter Meulen V.

J Virol. 2015 Dec 23;90(5):2162-4. doi: 10.1128/JVI.03045-15. Review.

12.

Genetic gain of function: EU report advises on contentious research.

Fears R, ter Meulen V.

Nature. 2015 Oct 29;526(7575):640. doi: 10.1038/526640d. No abstract available.

PMID:
26511570
13.

Antimicrobial innovation: combining commitment, creativity and coherence.

van der Meer JW, Fears R, Davies SC, ter Meulen V.

Nat Rev Drug Discov. 2014 Oct;13(10):709-10. doi: 10.1038/nrd4448.

PMID:
25270944
14.

What do we need to do to tackle antimicrobial resistance?

Fears R, ter Meulen V.

Lancet Glob Health. 2014 Jan;2(1):e11-2. doi: 10.1016/S2214-109X(13)70086-X. Epub 2013 Nov 18. No abstract available.

15.

Articulating the value of health research.

Fears R, Kelleher D, Tresguerres JA, Charpentier B, Popescu I, Souhami R.

QJM. 2014 Aug;107(8):603-5. doi: 10.1093/qjmed/hcu132. Epub 2014 Jun 26.

PMID:
24970762
16.

How should we tackle the global risks to plant health?

Fears R, Aro EM, Pais MS, ter Meulen V.

Trends Plant Sci. 2014 Apr;19(4):206-8. doi: 10.1016/j.tplants.2014.02.010.

PMID:
24698707
17.

Data protection regulation and the promotion of health research: getting the balance right.

Fears R, Brand H, Frackowiak R, Pastoret PP, Souhami R, Thompson B.

QJM. 2014 Jan;107(1):3-5. doi: 10.1093/qjmed/hct236. Epub 2013 Nov 19. No abstract available.

PMID:
24259722
18.

Reforming the EU environment for clinical trials: what are the challenges?

Fears R, Blum HE, Kelleher D, Meunier F, Souhami R.

QJM. 2013 Sep;106(9):787-9. doi: 10.1093/qjmed/hct149. Epub 2013 Jul 27. No abstract available.

PMID:
23893498
19.

Global networks: InterAcademy Panel to inform policy.

ter Meulen V, Hassan M, Fears R.

Nature. 2013 Jun 27;498(7455):434. doi: 10.1038/498434b. No abstract available.

PMID:
23803836
20.

The perspective from EASAC and FEAM on direct-to-consumer genetic testing for health-related purposes.

Fears R, ter Meulen V; EASAC–FEAM Working Group.

Eur J Hum Genet. 2013 Jul;21(7):703-7. doi: 10.1038/ejhg.2012.238. Epub 2012 Nov 21. Review.

21.

Nanosafety: How to allay fears over nanomaterials.

Fears R, Gehr P, Anklam E.

Nature. 2012 Aug 16;488(7411):281. doi: 10.1038/488281e. No abstract available.

PMID:
22895323
22.

The changing burden of infectious disease in Europe.

Fears R, van der Meer JW, ter Meulen V.

Sci Transl Med. 2011 Oct 5;3(103):103cm30. doi: 10.1126/scitranslmed.3002556.

PMID:
21974933
23.

European mental health policy: opportunities for science and innovation, challenges for implementation.

Fears R, Höschl C.

Eur J Public Health. 2011 Oct;21(5):550-1. doi: 10.1093/eurpub/ckr075. Epub 2011 Jul 20. No abstract available.

PMID:
21778147
24.

Health benefits of policies to mitigate climate change.

Fears R, ter Meulen V.

Lancet. 2011 Mar 19;377(9770):995-6. doi: 10.1016/S0140-6736(11)60385-1. No abstract available.

PMID:
21420552
25.

The potential of synthetic biology: a view from the European Academies Science Advisory Council.

Fears R, ter Meulen V.

Nat Rev Microbiol. 2011 Mar;9(3):222. doi: 10.1038/nrmicro2498-c1. No abstract available.

PMID:
21326277
26.

Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.

Fears R, Kaufmann S, Ter Meulen V, Zumla A; EASAC Working Group.

Tuberculosis (Edinb). 2010 May;90(3):182-7. doi: 10.1016/j.tube.2010.03.008. Epub 2010 Apr 10. Review.

PMID:
20382566
27.

Translational medicine policy issues in infectious disease.

Fears R, van der Meer JW, ter Meulen V.

Sci Transl Med. 2010 Jan 13;2(14):14cm2. doi: 10.1126/scitranslmed.3000375.

PMID:
20371464
28.

European bodies can help to tackle TB worldwide.

Fears R, Zumla A, ter Meulen V.

Nature. 2009 Aug 13;460(7257):796. doi: 10.1038/460796c. No abstract available.

PMID:
19675627
29.

Rational or rationed medicine? The promise of genetics for improved clinical practice.

Fears R, Roberts D, Poste G.

BMJ. 2000 Apr 1;320(7239):933-5. No abstract available.

30.

The impact of genetics on medical education and training.

Fears R, Weatherall D, Poste G.

Br Med Bull. 1999;55(2):460-70. Review.

PMID:
10723869
31.

Intraoperative breathing circuit obstruction caused by albuterol nebulization.

Walton JS, Fears R, Burt N, Dorman BH.

Anesth Analg. 1999 Sep;89(3):650-1. No abstract available.

PMID:
10475298
32.

Policy forum: health care delivery. Building populations genetics resources using the U.K. NHS.

Fears R, Poste G.

Science. 1999 Apr 9;284(5412):267-8. No abstract available.

PMID:
10232974
33.

Core ethical values for European bioindustries.

Fears R, Tambuyzer E.

Nat Biotechnol. 1999 Feb;17(2):114-5. No abstract available.

PMID:
10052333
34.

Life-sciences R&D, national prosperity, and industrial competitiveness.

Fears R, Ferguson MW, Stewart W, Poste G.

Science. 1997 May 2;276(5313):759-60. No abstract available.

PMID:
9157555
35.

Cardioprotection and thrombolysis by anistreplase in anesthetized dogs.

Feuerstein GZ, Nichols AJ, Valocik RE, Gagnon R, Sellars TS, Fears RC, Ferres H, Ruffolo RR Jr.

J Cardiovasc Pharmacol. 1995 Apr;25(4):625-33.

PMID:
7596132
36.

Chemical derivatization of therapeutic proteins.

Smith RA, Dewdney JM, Fears R, Poste G.

Trends Biotechnol. 1993 Sep;11(9):397-403. Review.

PMID:
7764087
37.

Evidence for more than one binding site in cloned D2 and D3 dopamine receptors.

Coldwell MC, Bowen WP, Brown F, Browne MJ, Fears R, Hadley MS, Hicks FR, Mannix CJ, Riley GJ.

Biochem Soc Trans. 1993 Feb;21(1):56S. No abstract available.

PMID:
8449339
38.

Why targeting? Physiological, pharmacological, and economic aspects.

Fears R.

Ann N Y Acad Sci. 1992 Dec 4;667:343-56. Review. No abstract available.

PMID:
1309055
40.
41.

Fibrinolytic activity in patients with diabetes mellitus: characterization of the effects of thrombolytic agents on plasma clot lysis in vitro.

Fears R, Standring R, Abraham R.

Semin Thromb Hemost. 1991 Oct;17(4):407-11. No abstract available.

PMID:
1803510
42.

Effect of heparin on the fibrinolytic response to plasminogen activators.

Fears R, Esmail AF, Greenwood HC.

Semin Thromb Hemost. 1991 Oct;17(4):389-93. Review. No abstract available.

PMID:
1803507
43.

A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.

Gemmill JD, Hogg KJ, Burns JM, Rae AP, Dunn FG, Fears R, Ferres H, Standring R, Greenwood H, Pierce D, et al.

Br J Clin Pharmacol. 1991 Feb;31(2):143-7.

44.
45.

Effects of novel bile salts on cholesterol metabolism in rats and guinea-pigs.

Fears R, Brown R, Ferres H, Grenier F, Tyrrell AW.

Biochem Pharmacol. 1990 Nov 1;40(9):2029-37.

PMID:
2242032
46.

Biochemical pharmacology and therapeutic aspects of thrombolytic agents.

Fears R.

Pharmacol Rev. 1990 Sep;42(3):201-22. Review. No abstract available.

PMID:
2120714
48.
49.

Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Fears R.

Biochem J. 1989 Jul 15;261(2):313-24. Review. No abstract available.

50.

Development of anisoylated plasminogen-streptokinase activator complex from the acyl enzyme concept.

Fears R.

Semin Thromb Hemost. 1989 Apr;15(2):129-39. Review. No abstract available.

PMID:
2665083

Supplemental Content

Support Center